{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 76,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/5",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "list",
      "text": "Partnered programmes: AI drug discovery collaboration with Merck KGaA; First milestone achieved in Sanofi collaboration; EXS4318, a PKC-theta inhibitor, is continuing in a Phase 1 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15f08b26-06ae-4480-a54f-f98fa50bf380",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "Technology updates: Presented data on automated kinase method; Novel automated discovery laboratory opened in Milton Park",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23babebf-626c-4277-b189-fbcb8c69a8d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.077,
        "y": 0.65
      },
      "kind": "list",
      "text": "Precision medicine: EXCYTE-1 ongoing trial in ovarian cancer; Collaboration with Charité to evaluate precision medicine in haematological cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60bd5010-e866-4326-8808-1298d52044eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.077,
        "y": 0.23
      },
      "kind": "list",
      "text": "Internal pipeline: Focus on differentiated, high value oncology targets; Enrollment ongoing in ELUCIDATE Phase 1/2 trial for CDK7 inhibitor; LSD1 inhibitor preparing for clinical start in 1H24; New preclinical data for LSD1 and MALT1 inhibitors presented at ESMO 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef2d5ce6-3763-4399-a37c-0f9354aeb05a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.285,
        "x": 0.077,
        "y": 0.065
      },
      "kind": "title",
      "text": "2023 Highlights YTD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81772d46-f22f-4431-a4d1-46279cc704d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a255625c-5b01-4d4f-b01d-e90906c29859",
      "evidence": "list/bullet: Internal pipeline: Focus on differentiated, high value oncology targets; Enrollment ongoing in ELUCIDATE Phase 1/2 trial for CDK7 inhibitor; LSD1 inhibitor preparing for clinical start in 1H24; New preclinic",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "74fe3472-17ea-4fa5-a09d-c82037044da9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents traction metrics on pages 4-6",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}